SRL and non-melanoma skin carcinoma: The latter might add to the mechanisms underlying the protective effects of SRL against proliferation of abnormal lymphoid cells and PTLD development, as well as against overall de novo malignancies and recurrent non-melanoma skin cancers as shown previously [16].